EC Pharmaceutical Strategy · September 03, 2025

Commission grants conditional authorisation for medicine treating Duchenne muscular dystrophy

Original title: Commission grants conditional authorisation medicine for treatment of Duchenne muscular dystrophy

European Commission granted conditional marketing authorisation for a medicine to treat Duchenne muscular dystrophy.

Low obligation Product class Pharmaceuticals EU-wide Pharmaceuticals

News announcement6 June 2025Commission grants conditional authorisation medicine for treatment of Duchenne muscular dystrophy1 min read

Read the official source ↗

Published by EC Pharmaceutical Strategy. HealthSignal links to the original document; the summary above is extracted from the source text.